T. Rowe Price Associates
PROK icon

T. Rowe Price Associates’s ProKidney PROK Stock Holding History

T. Rowe Price Associates’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127K Buy
+62,039
New +$114K ﹤0.01% 3108
2025
Q2 		– Sell
-43,108
Closed -$38K – 3130
2025
Q1 		$38K Buy
43,108
+2,630
+6% +$3.65K ﹤0.01% 2959
2024
Q4 		$69K Buy
40,478
+5,073
+14% +$9.15K ﹤0.01% 2892
2024
Q3 		$68K Buy
35,405
+16,211
+84% +$36.8K ﹤0.01% 2888
2024
Q2 		$48K Buy
19,194
+8,709
+83% +$23.4K ﹤0.01% 2861
2024
Q1 		$18K Hold
10,485
– – ﹤0.01% 2932
2023
Q4 		$19K Buy
+10,485
New +$22.5K ﹤0.01% 2875
2023
Q3 		– Sell
-12,501
Closed -$140K – 2907
2023
Q2 		$140K Buy
+12,501
New +$133K ﹤0.01% 2623

Other funds holding PROK

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $542M AUM 206.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

T. Rowe Price Associates's PROK Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in ProKidney (PROK) in Q2 2026: 62,039 shares worth $127K. The stake represents ﹤0.01% of the portfolio and ranks #3108 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in PROK as recently as Q1 2025.

T. Rowe Price Associates first reported a position in PROK in Q2 2023 and has held it in 8 quarters since. The position peaked at $140K in Q2 2023. 71 funds tracked by Wall St. Rank hold PROK as of Q2 2026.

  • T. Rowe Price Associates held 62,039 shares of ProKidney worth $127K as of Q2 2026.
  • ProKidney was a new T. Rowe Price Associates position in Q2 2026.
  • ProKidney made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3108 holding.
  • T. Rowe Price Associates first reported a position in ProKidney in Q2 2023 and has held it in 8 quarters since.
  • T. Rowe Price Associates's ProKidney position peaked at $140K in Q2 2023.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.